| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organoids | 4 | 2024 | 43 | 2.720 |
Why?
|
| Herpesvirus 1, Human | 2 | 2024 | 82 | 1.720 |
Why?
|
| Alzheimer Disease | 4 | 2024 | 721 | 1.330 |
Why?
|
| CRISPR-Cas Systems | 3 | 2023 | 361 | 1.310 |
Why?
|
| Autism Spectrum Disorder | 3 | 2022 | 180 | 1.150 |
Why?
|
| Genome-Wide Association Study | 9 | 2024 | 359 | 1.040 |
Why?
|
| Omentum | 1 | 2025 | 13 | 0.920 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2023 | 719 | 0.920 |
Why?
|
| Endometriosis | 1 | 2025 | 28 | 0.910 |
Why?
|
| Breast Neoplasms | 9 | 2024 | 1198 | 0.900 |
Why?
|
| Autistic Disorder | 4 | 2022 | 151 | 0.880 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 150 | 0.830 |
Why?
|
| Cell Movement | 1 | 2025 | 453 | 0.790 |
Why?
|
| Genetic Variation | 6 | 2017 | 383 | 0.770 |
Why?
|
| Brain | 4 | 2024 | 1556 | 0.760 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2020 | 67 | 0.720 |
Why?
|
| Induced Pluripotent Stem Cells | 4 | 2025 | 148 | 0.720 |
Why?
|
| Genes, Recessive | 3 | 2019 | 52 | 0.690 |
Why?
|
| Transcriptome | 4 | 2024 | 387 | 0.660 |
Why?
|
| Mutation, Missense | 2 | 2019 | 186 | 0.650 |
Why?
|
| Intellectual Disability | 1 | 2022 | 172 | 0.630 |
Why?
|
| Gene Editing | 1 | 2023 | 321 | 0.590 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2013 | 45 | 0.580 |
Why?
|
| Databases, Genetic | 1 | 2017 | 89 | 0.520 |
Why?
|
| Humans | 54 | 2025 | 63467 | 0.490 |
Why?
|
| Exome | 9 | 2018 | 77 | 0.470 |
Why?
|
| Genetics, Population | 2 | 2014 | 44 | 0.470 |
Why?
|
| Group II Chaperonins | 1 | 2014 | 2 | 0.460 |
Why?
|
| Genotype | 5 | 2023 | 665 | 0.450 |
Why?
|
| Founder Effect | 1 | 2014 | 11 | 0.450 |
Why?
|
| Genetic Drift | 1 | 2014 | 16 | 0.450 |
Why?
|
| Herpes Simplex | 2 | 2024 | 50 | 0.440 |
Why?
|
| Single-Cell Analysis | 3 | 2025 | 114 | 0.440 |
Why?
|
| Models, Genetic | 2 | 2014 | 260 | 0.430 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 38 | 0.430 |
Why?
|
| Mutation | 9 | 2024 | 2609 | 0.420 |
Why?
|
| Sequence Analysis, RNA | 3 | 2024 | 174 | 0.410 |
Why?
|
| Microglia | 3 | 2025 | 242 | 0.410 |
Why?
|
| Loss of Heterozygosity | 1 | 2013 | 24 | 0.400 |
Why?
|
| Gene Deletion | 2 | 2018 | 308 | 0.400 |
Why?
|
| Demography | 1 | 2013 | 173 | 0.390 |
Why?
|
| Precision Medicine | 2 | 2023 | 118 | 0.350 |
Why?
|
| Female | 33 | 2025 | 32889 | 0.350 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 166 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2023 | 491 | 0.310 |
Why?
|
| Phenotype | 7 | 2023 | 1207 | 0.310 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 674 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2014 | 696 | 0.290 |
Why?
|
| Obesity | 2 | 2014 | 1234 | 0.270 |
Why?
|
| Neoplasms | 4 | 2022 | 1364 | 0.260 |
Why?
|
| Gene Frequency | 3 | 2018 | 123 | 0.260 |
Why?
|
| Multifactorial Inheritance | 3 | 2015 | 26 | 0.250 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2025 | 18 | 0.230 |
Why?
|
| Culture Media, Conditioned | 1 | 2025 | 51 | 0.230 |
Why?
|
| Vagus Nerve | 1 | 2024 | 21 | 0.230 |
Why?
|
| Antigens, CD | 2 | 2024 | 347 | 0.230 |
Why?
|
| Finland | 2 | 2014 | 20 | 0.230 |
Why?
|
| Immunoglobulins | 1 | 2024 | 77 | 0.220 |
Why?
|
| Neovascularization, Pathologic | 1 | 2025 | 140 | 0.220 |
Why?
|
| Cytomegalovirus | 1 | 2024 | 91 | 0.220 |
Why?
|
| Resistance Training | 1 | 2024 | 22 | 0.210 |
Why?
|
| Cognitive Dysfunction | 2 | 2018 | 331 | 0.210 |
Why?
|
| Exons | 3 | 2018 | 199 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 313 | 0.210 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2023 | 7 | 0.200 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2023 | 41 | 0.200 |
Why?
|
| Islets of Langerhans | 1 | 2024 | 279 | 0.200 |
Why?
|
| Pluripotent Stem Cells | 1 | 2023 | 74 | 0.200 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 459 | 0.200 |
Why?
|
| Stem Cells | 1 | 2024 | 259 | 0.200 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 230 | 0.200 |
Why?
|
| Middle Aged | 12 | 2025 | 17609 | 0.190 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 57 | 0.190 |
Why?
|
| Chromosome Disorders | 1 | 2022 | 14 | 0.190 |
Why?
|
| Case-Control Studies | 6 | 2019 | 1121 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2022 | 25 | 0.190 |
Why?
|
| Odds Ratio | 4 | 2021 | 768 | 0.190 |
Why?
|
| Gene Regulatory Networks | 2 | 2025 | 158 | 0.190 |
Why?
|
| Chromosome Deletion | 1 | 2022 | 42 | 0.190 |
Why?
|
| Transcription Factors | 2 | 2025 | 1513 | 0.190 |
Why?
|
| Cell Differentiation | 2 | 2025 | 1353 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 143 | 0.180 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 507 | 0.180 |
Why?
|
| DNA, Mitochondrial | 2 | 2023 | 87 | 0.180 |
Why?
|
| DNA Methylation | 1 | 2023 | 292 | 0.180 |
Why?
|
| Singapore | 4 | 2024 | 13 | 0.180 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 669 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 87 | 0.180 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 158 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2023 | 770 | 0.180 |
Why?
|
| Adult | 10 | 2025 | 16830 | 0.180 |
Why?
|
| Flow Cytometry | 1 | 2023 | 664 | 0.170 |
Why?
|
| Prognosis | 6 | 2022 | 1748 | 0.170 |
Why?
|
| Cell Proliferation | 1 | 2025 | 988 | 0.170 |
Why?
|
| Fatigue | 2 | 2018 | 111 | 0.170 |
Why?
|
| Neurons | 2 | 2019 | 922 | 0.160 |
Why?
|
| Mitochondria | 1 | 2023 | 371 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2019 | 346 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2019 | 16 | 0.160 |
Why?
|
| Exercise | 2 | 2024 | 942 | 0.160 |
Why?
|
| Allelic Imbalance | 1 | 2019 | 7 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 621 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 37 | 0.160 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 110 | 0.150 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2018 | 9 | 0.150 |
Why?
|
| Homozygote | 3 | 2014 | 124 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 59 | 0.150 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2024 | 504 | 0.150 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 45 | 0.150 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 35 | 0.150 |
Why?
|
| Male | 15 | 2024 | 29906 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2019 | 226 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 73 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 40 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 456 | 0.140 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2018 | 57 | 0.140 |
Why?
|
| Plasma Cells | 1 | 2018 | 53 | 0.140 |
Why?
|
| Extracellular Vesicles | 1 | 2018 | 45 | 0.140 |
Why?
|
| Zebrafish | 3 | 2018 | 347 | 0.140 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 81 | 0.140 |
Why?
|
| Likelihood Functions | 2 | 2014 | 69 | 0.140 |
Why?
|
| Genome, Human | 5 | 2019 | 237 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2018 | 110 | 0.140 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 111 | 0.140 |
Why?
|
| Mosaicism | 1 | 2017 | 30 | 0.140 |
Why?
|
| Zygote | 1 | 2017 | 45 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2018 | 153 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 525 | 0.130 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 896 | 0.130 |
Why?
|
| Quality of Life | 1 | 2024 | 1228 | 0.130 |
Why?
|
| Mitosis | 1 | 2018 | 217 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2025 | 3036 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2018 | 1996 | 0.130 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 5462 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 448 | 0.120 |
Why?
|
| Aged | 9 | 2024 | 14443 | 0.120 |
Why?
|
| Histones | 1 | 2019 | 481 | 0.120 |
Why?
|
| Autophagy | 1 | 2018 | 225 | 0.120 |
Why?
|
| Pedigree | 5 | 2013 | 193 | 0.120 |
Why?
|
| Gene Silencing | 1 | 2018 | 400 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 864 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 5 | 2014 | 415 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 574 | 0.120 |
Why?
|
| Body Height | 1 | 2015 | 68 | 0.110 |
Why?
|
| Chaperonins | 1 | 2014 | 6 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1617 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2020 | 2569 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2021 | 879 | 0.110 |
Why?
|
| Oligonucleotides | 1 | 2016 | 221 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2013 | 220 | 0.110 |
Why?
|
| Dependovirus | 1 | 2021 | 709 | 0.110 |
Why?
|
| HEK293 Cells | 4 | 2018 | 622 | 0.110 |
Why?
|
| Heterozygote | 1 | 2014 | 170 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 57 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 422 | 0.110 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hypoparathyroidism | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hypogonadism | 1 | 2013 | 14 | 0.100 |
Why?
|
| Ataxia | 1 | 2013 | 23 | 0.100 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 74 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 663 | 0.100 |
Why?
|
| Animals | 9 | 2021 | 20664 | 0.100 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 47 | 0.100 |
Why?
|
| Diarrhea, Infantile | 1 | 2012 | 3 | 0.100 |
Why?
|
| Risk Factors | 4 | 2023 | 5356 | 0.100 |
Why?
|
| Diacylglycerol O-Acyltransferase | 1 | 2012 | 12 | 0.100 |
Why?
|
| Chromosomes, Human, X | 1 | 2013 | 36 | 0.100 |
Why?
|
| Ubiquitination | 1 | 2013 | 111 | 0.100 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 1 | 2012 | 4 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2014 | 111 | 0.100 |
Why?
|
| DNA Damage | 1 | 2014 | 287 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2014 | 265 | 0.090 |
Why?
|
| Potassium Channels | 1 | 2012 | 58 | 0.090 |
Why?
|
| Glycine Dehydrogenase (Decarboxylating) | 1 | 2012 | 3 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2013 | 268 | 0.090 |
Why?
|
| Genetic Association Studies | 3 | 2018 | 120 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 206 | 0.080 |
Why?
|
| Algorithms | 3 | 2023 | 1003 | 0.080 |
Why?
|
| Dementia | 1 | 2013 | 260 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2016 | 687 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2025 | 2157 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2020 | 234 | 0.080 |
Why?
|
| Mice | 6 | 2021 | 10844 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2022 | 255 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1186 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2019 | 583 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2023 | 2081 | 0.060 |
Why?
|
| Alleles | 2 | 2018 | 448 | 0.060 |
Why?
|
| Interferon Regulatory Factors | 1 | 2025 | 43 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2025 | 78 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 66 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1654 | 0.050 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2024 | 10 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2024 | 40 | 0.050 |
Why?
|
| Biological Variation, Population | 1 | 2023 | 9 | 0.050 |
Why?
|
| Olfactory Pathways | 1 | 2023 | 5 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2023 | 15 | 0.050 |
Why?
|
| Profilins | 1 | 2024 | 45 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2023 | 34 | 0.050 |
Why?
|
| Dystrophin | 1 | 2023 | 31 | 0.050 |
Why?
|
| United Kingdom | 1 | 2023 | 81 | 0.050 |
Why?
|
| Biological Specimen Banks | 1 | 2023 | 23 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2024 | 104 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 3294 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2023 | 41 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 35 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 1277 | 0.050 |
Why?
|
| CpG Islands | 1 | 2023 | 216 | 0.050 |
Why?
|
| Iron | 1 | 2022 | 148 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 1469 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 17 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2018 | 1358 | 0.040 |
Why?
|
| Child | 3 | 2018 | 4534 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 58 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 110 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2021 | 134 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 107 | 0.040 |
Why?
|
| Base Sequence | 1 | 2023 | 1331 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1008 | 0.040 |
Why?
|
| Breast | 1 | 2022 | 183 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 771 | 0.040 |
Why?
|
| Pathologists | 1 | 2020 | 14 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 376 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 370 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 25 | 0.040 |
Why?
|
| Keratins | 1 | 2019 | 31 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 59 | 0.040 |
Why?
|
| Microfluidics | 1 | 2019 | 25 | 0.040 |
Why?
|
| Cell Count | 1 | 2019 | 132 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 56 | 0.040 |
Why?
|
| Nuclear Lamina | 1 | 2019 | 11 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cell Line | 1 | 2023 | 2040 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 242 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 37 | 0.040 |
Why?
|
| Genes, Synthetic | 1 | 2018 | 6 | 0.040 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 48 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2018 | 43 | 0.040 |
Why?
|
| Choroid Plexus | 1 | 2018 | 16 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2018 | 51 | 0.040 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 109 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2021 | 321 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2018 | 69 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 37 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 63 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 99 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2019 | 64 | 0.040 |
Why?
|
| Aging | 1 | 2024 | 745 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2018 | 58 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2018 | 9 | 0.040 |
Why?
|
| Sample Size | 1 | 2018 | 65 | 0.040 |
Why?
|
| Anthracyclines | 1 | 2018 | 12 | 0.040 |
Why?
|
| Taxoids | 1 | 2018 | 26 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 277 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 196 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 152 | 0.030 |
Why?
|
| Infant | 2 | 2012 | 1648 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2018 | 152 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 2018 | 113 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 4696 | 0.030 |
Why?
|
| Geography | 1 | 2017 | 37 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2017 | 26 | 0.030 |
Why?
|
| Disease | 1 | 2017 | 27 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 125 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 394 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 936 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 297 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 489 | 0.030 |
Why?
|
| Ribosomes | 1 | 2018 | 163 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 883 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 694 | 0.030 |
Why?
|
| Quinazolines | 1 | 2016 | 22 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 222 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 39 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2016 | 21 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 509 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 69 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 88 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 840 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 190 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 477 | 0.030 |
Why?
|
| Leg Bones | 1 | 2015 | 2 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 425 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 6253 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 341 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 796 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 58 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 203 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1380 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 935 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 115 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 289 | 0.030 |
Why?
|
| Albuminuria | 1 | 2014 | 31 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2014 | 114 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1408 | 0.030 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 37 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2021 | 791 | 0.030 |
Why?
|
| Consanguinity | 1 | 2013 | 6 | 0.030 |
Why?
|
| Population Control | 1 | 2013 | 3 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2013 | 57 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2013 | 96 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 377 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2013 | 122 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2019 | 1537 | 0.020 |
Why?
|
| RNA Splice Sites | 1 | 2012 | 23 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 92 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 124 | 0.020 |
Why?
|
| Clathrin Heavy Chains | 1 | 2012 | 3 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 308 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2012 | 53 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 33 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 309 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 197 | 0.020 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 35 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 205 | 0.020 |
Why?
|
| Fetal Proteins | 1 | 2012 | 9 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 48 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 126 | 0.020 |
Why?
|
| Thermus thermophilus | 1 | 2012 | 21 | 0.020 |
Why?
|
| Glycine | 1 | 2012 | 49 | 0.020 |
Why?
|
| Family Health | 1 | 2012 | 69 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2012 | 98 | 0.020 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2012 | 23 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1172 | 0.020 |
Why?
|
| Serine | 1 | 2012 | 91 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 229 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 299 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 6659 | 0.020 |
Why?
|
| Software | 1 | 2013 | 389 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 429 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2013 | 1149 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2679 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 1981 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 1592 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 1991 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 435 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 878 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2014 | 791 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3396 | 0.010 |
Why?
|
| United States | 1 | 2017 | 7842 | 0.010 |
Why?
|